Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q1 FY27 results · Apr–Jun 2026
Sun Pharma Advanced Research Company reported revenue from operations of ₹39.92 crore (up 314.1% from Q1 FY26) and net loss of ₹20.78 crore for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 39.92 | 9.64 | +314.1% | 1,853.22 | −97.8% |
| Other income | 23.66 | 9.14 | +158.9% | 1.80 | 13x |
| Total income | 63.58 | 18.78 | +238.6% | 1,855.02 | −96.6% |
| Profit before tax | (20.67) | (51.81) | Loss narrowed | 1,760.96 | Turned loss |
| Net profit for the period | (20.78) | (51.87) | Loss narrowed | 1,761.34 | Turned loss |
| Attributable to shareholders of the company | (20.76) | — | — | 1,762.69 | Turned loss |
| EPS, basic (₹) | (0.64) | (1.60) | Loss narrowed | 54.27 | Turned loss |
| Net margin (%) | -52.1 | -538.1 | 95.0 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 39.92 | 9.64 | +314.1% | 1,853.22 | −97.8% |
| Other income | 23.66 | 9.02 | +162.3% | 1.80 | 13x |
| Total income | 63.58 | 18.66 | +240.7% | 1,855.02 | −96.6% |
| Profit before tax | (20.98) | (52.03) | Loss narrowed | 1,760.70 | Turned loss |
| Net profit for the period | (20.98) | (52.03) | Loss narrowed | 1,760.70 | Turned loss |
| EPS, basic (₹) | (0.65) | (1.60) | Loss narrowed | 54.26 | Turned loss |
| Net margin (%) | -52.6 | -539.7 | 95.0 |
Consolidated
- Filed with BSE
- 10 Aug 2026, 14:52 IST
- Board meeting
- 10 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Aug 2026, 14:52 IST
- Board meeting
- 10 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE